Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Thomas Decker1, Ulrike Söling2, Antje Hahn3, Christoph Maintz4, Christian Martin Kurbacher5, Ursula Vehling-Kaiser6, Dagmar Sent7, Peter Klare8, Volker Hagen9, Marco Chiabudini10, Julia Falkenstein10, Martin Indorf10, Eva Runkel10 and Karin Potthoff10*

Abstract

Background: The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer.

Methods: In this randomized, cross-over phase IV study, 77 patients were recruited in 26 sites in Germany. Patients were randomized 1:1 to receive either capecitabine plus bevacizumab (Cap+Bev) as first-line therapy followed by cross-over to everolimus plus exemestane (Eve+Exe) as second-line therapy (Arm A) or the reverse sequence (Arm B). The primary endpoint was patients’ preference for either regimen, assessed by the Patient Preference Questionnaire 12 weeks after cross-over. Key secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and quality of life (QoL).

(Continued on next page)
Background
Breast cancer (BC) is the second-most common cancer worldwide. Approximately 20–30% of all patients treated with curative intent develop metastatic BC (MBC) [1]. Depending on subtype, systemic treatment of advanced BC (locally recurrent and inoperable or MBC) offers a wide range of options including endocrine therapy, immunotherapy, kinase inhibitors, radiation therapy, and supportive measures. For postmenopausal patients with advanced hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) BC various treatment options exist. Current international guidelines recommend endocrine therapy as the first-line treatment of choice in the vast majority of these patients. Chemotherapy may be considered as a reasonable alternative in patients for whom endocrine treatment is inappropriate including individuals presenting with acute visceral crisis and/or hormone-resistant tumors [2–4]. Up to now, there are limited data from clinical trials having directly compared chemotherapy and endocrine-based treatment in patients with MBC. A previous metaanalysis reported similar efficacy of both treatment strategies, however, the drugs utilized were outdated as per today’s standard of care [5].

Capecitabine (Cap) + bevacizumab (Avastin®, Bev) combination therapy is indicated for first-line treatment of adult patients with MBC for whom treatment with taxanes and/or anthracyclines is inappropriate [6–9]. Regarding endocrine therapy, the everolimus (Afinitor®, Eve) + exemestane (Aromasin®, Exe) combination is indicated in postmenopausal patients with advanced HR-positive, HER2-negative BC after recurrence or progression following treatment with non-steroidal aromatase inhibitors [10–13].

Assuming comparable efficacy between different therapeutic options, it is of utmost importance to identify the treatment with the least negative impact on patients’ quality of life (QoL). The IMPROVE study evaluated patients’ preference for either combined antihormonal therapy (everolimus + exemestane, Eve+Exe) or combined chemo- and anti-angiogenic therapy (capecitabine + bevacizumab, Cap+Bev) in postmenopausal patients with advanced HR-positive, HER2-negative BC and indication for first-line chemotherapy or endocrine therapy after failure of ≥1 standard non-steroidal aromatase inhibitor therapy.

Methods
Patients
Eligible patients were aged ≥18 years, postmenopausal, diagnosed with HR-positive, HER2-negative advanced BC (locally recurrent and inoperable or MBC), with indication for first-line chemotherapy or endocrine therapy after failure of ≥1 non-steroidal aromatase inhibitor therapy, no indication for treatment with taxanes and/or anthracyclines, measurable or non-measurable disease according to RECIST v1.1 [14], adequate bone marrow and organ function as per current Summary of Product Characteristics (SmPC) of respective study drug [8, 9, 12, 13], ECOG performance status ≤2, and fluency in German. Key exclusion criteria included prior palliative cytotoxic chemotherapy, prior treatment with mTOR (mammalian target of rapamycin)-inhibitors (prior treatment with exemestane was permitted), symptomatic visceral metastases, unstable skeletal metastases, medically uncontrolled cardiovascular diseases or diabetes mellitus, and known dihydropyrimidine dehydrogenase deficiency.

Study design and endpoints
This open-label, randomized, controlled, multicenter, two-arm, cross-over phase IV study (EudraCT No 2013–005329-22) randomly assigned patients (1:1) to receive either Cap+Bev first-line therapy during the first treatment phase (TP) followed by cross-over to Eve+Exe as second-line therapy during the second TP (Arm A) or the reverse
sequence (Arm B; Fig. 1). For allocation of patients, a computer-generated randomization list was used to automatically allocate patients in the electronic Case Report Form by using an integrated randomization tool within the Electronic Data Capture system. Patients were stratified by (i) visceral metastases versus non-visceral metastases, (ii) prior (neo) adjuvant treatment (anthracycline and/or taxane; yes versus no), (iii) number of prior palliative anti-hormonal therapies (0–1 versus > 1) and (iv) disease-free interval (DFI; ≤2 years versus > 2 years) by using a permuted block randomization with block lengths of two and four. DFI was defined as the time from first R0 resection until first local relapse or occurrence of distant metastases, whichever occurred first. The block sizes were not disclosed to ensure concealment. Patients were treated in each TP until progression, intolerable toxicity, or withdrawal of consent. Each TP was separated by a washout phase (7–28 days). Dosing and administration of the study drugs are detailed in Table 1.

The primary endpoint was patients’ preference for either Cap+Bev or Eve+Exe combination therapy, assessed by questionnaire 12 weeks after cross over. Key secondary endpoints included progression-free survival (PFS), overall survival (OS), treatment satisfaction, QoL, and safety.

Questionnaires
Patients’ treatment preference was assessed by the Patient Preference Questionnaire (PPQ) 12 weeks after cross over. Patients having discontinued therapy after < 12 weeks of treatment were asked to complete the PPQ within 2 weeks of treatment discontinuation. Patients were asked in the PPQ for their treatment preference (Cap+Bev, Eve+Exe, or no preference) and reason for their preference. Similarly, physicians were asked for their treatment preference (case-based), assessed by the Physician Preference Questionnaire. Patients were asked to complete the Treatment Satisfaction Questionnaire in week 12 of each TP. Additionally, patients were asked to complete QoL questionnaires in each TP (baseline and at week 12) including the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire [15].

Tumor assessment and adverse events
Tumor evaluation according to RECIST v1.1 was to be performed by the investigator at screening, every 12 weeks and at end of each TP, and every 6 months during

---

**Table 1** Dose and mode of administration of the study drugs

| Study drug   | Dose and mode of administration                                                                 |
|--------------|--------------------------------------------------------------------------------------------------|
| Capcitabine  | 1000 mg/m² per os twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a 7-day resting period (i.e. off-treatment) |
| Bevacizumab  | 15 mg/kg intravenously once every 3 weeks (i.e. 5 mg/kg/week dose equivalent)                     |
| Everolimus   | 10 mg per os once daily of each 21-day cycle                                                       |
| Exemestane   | 25 mg per os once daily of each 21-day cycle                                                       |

*Dose and mode of administration of the study drugs were in accordance with current SmPC of respective study drug. Study drugs were available upon prescription by respective treating physician. A cycle was defined as 21 days of study treatment.*
follow-up (FU; ≥24 months or until death). During the FU, patients were also assessed for survival status. Any treatment-emergent adverse event (TEAE) and toxicity were to be recorded from day of first administration of study treatment until 30 days after end of treatment in each TP. TEAEs were graded by the investigator according to NCI CTCAE v4.03 [16].

**Statistical analysis**

The initial null hypothesis stated that there is no difference in patients’ preference for either regimen assuming that 80% of patients do have a preference, whereas 20% cannot decide. The study was designed to control the α error rate at 0.05 with a power of 80%. Required sample size was estimated to 192 patients assuming a drop-out rate at 35%. The assumptions for the null hypotheses were chosen according to the PISCES trial [17].

The intent-to-treat (ITT) population comprised all patients to whom study treatment had been assigned by randomization. The modified ITT (mITT) population was used to assess the primary endpoint and was predefined as all patients who had received both first-line and second-line therapy for ≥12 weeks per line or less for other reasons than progressive disease (PD), crossed over to second-line therapy within 12 weeks of termination of first-line therapy, and answered the preference question. Additionally, the primary endpoint was assessed in a post hoc analysis by using the per-protocol (PP) population including all patients who had received ≥1 dose of study medication in first-line and second-line therapy and answered the preference question. The safety set (SAF) included all patients who had received ≥1 dose of study medication.

To analyze the primary endpoint and to test the significance of difference in patient preference between the regimens, a Chi-square test was used to compare the actual preference against the null hypothesis of no difference in patient preference taking into account the proportion of indifferent patients. For the final analysis, the null hypothesis was adopted for the actually observed proportion of indifferent patients. By this means, the actual null hypothesis for
the primary analysis was 38.45% prefer Cap+Bev, 38.45% prefer Eve+Exe, and 23.1% are indifferent about their preference. Reasons for preference were analyzed descriptively.

Difference in overall treatment satisfaction was analyzed by using an asymptotic chi-square test (satisfied versus not satisfied).

The EORTC QLQ-C30 questionnaire was analyzed descriptively. Differences in scores were evaluated by a t-test. PFS and OS were estimated by using the Kaplan-Meier method [18].

The primary endpoint was further evaluated by age (<60 years vs. ≥60 years) in the mITT, ITT and PP populations. However, further subgroup and explorative analyses pre-planned for the primary endpoint were not performed due to low number of available observations (mITT; N = 13).

Results

This study was initially planned to enroll 192 patients. Due to emergence of new treatment options and low recruitment rate, the recruitment was stopped after 77 patients had been randomized. The study was prematurely terminated in September 2017.

Disposition of patients

Seventy-seven patients (ITT population) were recruited from October 2014 through April 2017 in 26 sites in Germany (Fig. 2); 39 patients were randomized to Arm A (Cap+Bev / Eve+Exe) and 38 patients to Arm B (Eve+Exe / Cap+Bev). In Arm A, 37 of the 39 randomized patients received the allocated first-line therapy. Of these, 17 patients crossed over to second-line therapy. In Arm B, 37 of the 38 randomized patients received the allocated first-line therapy. Of these, 19 patients crossed over to second-line therapy. Overall, 44 patients started the FU, which was planned to last ≥24 months or until death (FU completed: n = 21).

The mITT population comprised 13 patients (Arm A: N = 5; Arm B: N = 8) and the PP population 31 patients (Arm A: N = 13; Arm B: N = 18). The SAF population was used to analyze TEAEs in first-line (Arm A: N = 37; Arm B: N = 37) and second-line therapy (Arm A: N = 17; Arm B: N = 19).

**Table 2** Patient characteristics at baseline (ITT population)

|                          | Arm A (Cap+Bev / Eve+Exe) (N = 39) | Arm B (Eve+Exe / Cap+Bev) (N = 38) |
|--------------------------|----------------------------------|----------------------------------|
| Age [years], median (range) | 64.4 (47.0–83.6)                  | 65.9 (49.9–86.0)                  |
| Ethnicity, n (%)          |                                   |                                  |
| Caucasian                 | 38 (97.4%)                        | 37 (97.4%)                       |
| Asian                     | 1 (2.6%)                          | 1 (2.6%)                         |
| BMI (kg/m²), median (quartiles) | 25.6 (22.5–28.4)                  | 24.9 (22.7–31.1)                  |
| ECOG Performance Status, n (%) |                                   |                                  |
| 0                        | 19 (48.7%)                        | 17 (44.7%)                       |
| 1                        | 19 (48.7%)                        | 20 (52.6%)                       |
| 2                        | 1 (2.6%)                          | 1 (2.6%)                         |
| Menopausal status, n (%)  |                                   |                                  |
| Postmenopausal            | 39 (100%)                         | 38 (100%)                        |
| Concomitant diseases, n (%) |                                   |                                  |
| Yes                      | 33 (84.6%)                        | 35 (92.1%)                       |
| No                       | 6 (15.4%)                         | 3 (7.9%)                         |
| Visceral disease or local relapse, n (%) | 27 (69.2%)                      | 26 (68.4%)                       |
| Non-visceral disease, n (%) | 12 (30.8%)                       | 12 (31.6%)                       |
| Metastatic sites*, n (%)  |                                   |                                  |
| Bone                     | 28 (71.8%)                        | 29 (76.3%)                       |
| Liver                    | 15 (38.5%)                        | 16 (42.1%)                       |
| Lung                     | 8 (20.5%)                         | 10 (26.3%)                       |
| Histology of tumor, n (%) |                                   |                                  |
| Invasive ductal           | 27 (69.2%)                        | 24 (63.2%)                       |
| Invasive lobular          | 7 (17.9%)                         | 12 (31.6%)                       |
| Inflammatory cancer       | 1 (2.6%)                          | 0                                |
| Not otherwise specified   | 4 (10.3%)                         | 2 (5.3%)                         |
| DFI¹ [years], median (quartiles) | 4.7 (1.4–10.9)                   | 5.0 (1.3–8.2)                    |
| Time since initial diagnosis [years], median (quartiles) | 9.6 (3.6–13.0)                  | 6.6 (2.5–10.0)                   |
| Time since first relapse² [years], median (quartiles) | 8.4 (0.6–23.4)                  | 5.1 (1.5–15.1)                   |
| Any prior adjuvant chemotherapy, n (%) | 22 (56.4%)                     | 28 (73.7%)                       |
| Prior adjuvant taxane and/or anthracycline therapy, n (%) | 22 (56.4%)                     | 26 (68.4%)                       |
| Number of prior palliative endocrine therapies, n (%) |                                   |                                  |
| 1                        | 10 (25.6%)                        | 13 (34.2%)                       |
| 2                        | 11 (28.2%)                        | 10 (26.3%)                       |
| 3                        | 1 (2.6%)                          | 0                                |

*Multiple answers per patient were possible. ¹DFI was defined as the time from first R0 resection until first local relapse or occurrence of distant metastases, whichever occurred first. ²Includes both local breast cancer recurrence and distant metastases. BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; DFI = disease-free interval

Patient characteristics at baseline

All patients had HR-positive, HER2-negative BC. Baseline patient demographics, clinical characteristics, and treatment history in the randomized ITT population were balanced between study arms (Table 2).
Patients' preference

Overall, 61.5% of patients reported Cap+Bev as their preferred regimen, though not statistically significant (mITT, \(p = 0.1653\), Table 3). In Arm A and Arm B, 40% and 75% of patients reported Cap+Bev as their preferred therapy versus Eve+Exe (Arm A: 20.0%; Arm B: 12.5%), respectively. Overall, a similar tendency towards Cap+Bev as the preferred regimen was observed in the PP and ITT populations (Table 3). Notably, 10 of the 13 patients preferring Cap+Bev were found in Arm B.

The main reason for preference was improved QoL reported both among patients (ITT population) having preferred Cap+Bev (\(n = 9; 69.2\%\)) or Eve+Exe (\(n = 3; 42.9\%\)).

### Table 3

| Table 3 | Rates of patients’ preference\(^a\) (mITT/ITT/PP population) |
|---------|-------------------------------------------------------------|
|         | mITT | Arm A (\(N = 5\)) | Arm B (\(N = 8\)) | Total (\(N = 13\)) |
|         | n (%) | 95%-CI | n (%) | 95%-CI | n (%) | 95%-CI |
| Cap+Bev | 2 (40.0\%) | [5.3, 85.3] | 6 (75.0\%) | [34.9, 96.8] | 8 (61.5\%) | [31.6, 86.1] |
| Eve+Exe | 1 (20.0\%) | [0.5, 71.6] | 1 (12.5\%) | [0.3, 52.7] | 2 (15.4\%) | [1.9, 45.4] |
| I cannot decide | 2 (40.0\%) | [5.3, 85.3] | 1 (12.5\%) | [0.3, 52.7] | 3 (23.1\%) | [5.0, 53.8] |
| p-value (Chi-square) | 0.1653 | | | |
| ITT | Arm A (\(N = 39\)) | Arm B (\(N = 38\)) | Total (\(N = 77\)) |
| n (%) | 95%-CI | n (%) | 95%-CI | n (%) | 95%-CI |
| Cap+Bev | 3 (7.7\%) | [1.6, 20.9] | 10 (26.3\%) | [13.4, 43.1] | 13 (16.9\%) | [9.3, 27.1] |
| Eve+Exe | 5 (12.8\%) | [4.3, 27.4] | 2 (5.3\%) | [0.6, 17.7] | 7 (9.1\%) | [3.7, 17.8] |
| I cannot decide | 3 (7.7\%) | [1.6, 20.9] | 4 (10.5\%) | [2.9, 24.8] | 7 (9.1\%) | [3.7, 17.8] |
| Not evaluable | 2 (5.1\%) | [0.6, 17.3] | 2 (5.3\%) | [0.6, 17.7] | 4 (5.2\%) | [1.4, 12.8] |
| Item / questionnaire not answered | 4 (10.3\%) | [2.9, 24.2] | 1 (2.6\%) | [0.1, 13.8] | 5 (6.5\%) | [2.1, 14.5] |
| No second-line therapy | 22 (56.4\%) | [39.6, 72.2] | 19 (50.0\%) | [33.4, 66.6] | 41 (53.2\%) | [41.5, 64.7] |
| PP | Arm A (\(N = 13\)) | Arm B (\(N = 18\)) | Total (\(N = 31\)) |
| n (%) | 95%-CI | n (%) | 95%-CI | n (%) | 95%-CI |
| Cap+Bev | 3 (23.1\%) | [5.0, 53.8] | 10 (55.6\%) | [30.8, 78.5] | 13 (41.9\%) | [24.5, 60.9] |
| Eve+Exe | 5 (38.5\%) | [13.9, 68.4] | 2 (11.1\%) | [1.4, 34.7] | 7 (22.6\%) | [9.6, 41.1] |
| I cannot decide | 3 (23.1\%) | [5.0, 53.8] | 4 (22.2\%) | [6.4, 47.6] | 7 (22.6\%) | [9.6, 41.1] |
| Not evaluable | 2 (15.4\%) | [1.9, 45.4] | 2 (11.1\%) | [1.4, 34.7] | 4 (12.9\%) | [3.6, 29.8] |

*Patient’s treatment preference was evaluated after 12 weeks of second-line treatment, assessed by the Patient Preference Questionnaire. Confidence interval was calculated using the Clopper-Pearson formula. Due to small n, the p-value of the asymptotic chi-square test may not be valid. The p-value of the corresponding exact test was 0.1666. Not evaluable: Patients selected more than one possible answer. mITT = modified ITT; ITT = intent-to-treat; PP = per-protocol; CI = confidence interval

### Table 4

| Table 4 | Rates of physician’s preference\(^a\) (mITT/ITT/PP population) |
|---------|-------------------------------------------------------------|
|         | mITT | Arm A (\(N = 5\)) | Arm B (\(N = 8\)) | Total (\(N = 13\)) |
|         | n (%) | 95%-CI | n (%) | 95%-CI | n (%) | 95%-CI |
| Cap+Bev | 3 (60.0\%) | [14.7, 94.7] | 3 (37.5\%) | [8.5, 75.5] | 6 (46.2\%) | [19.2, 74.9] |
| Eve+Exe | 2 (40.0\%) | [5.3, 85.3] | 2 (25.0\%) | [3.2, 65.1] | 4 (30.8\%) | [9.1, 61.4] |
| I cannot decide | 0 | | 3 (37.5\%) | [8.5, 75.5] | 3 (23.1\%) | [5.0, 53.8] |
| ITT | Arm A (\(N = 39\)) | Arm B (\(N = 38\)) | Total (\(N = 77\)) |
| n (%) | 95%-CI | n (%) | 95%-CI | n (%) | 95%-CI |
| Cap+Bev | 10 (25.6\%) | [13.0, 42.1] | 10 (26.3\%) | [13.4, 43.1] | 20 (26.0\%) | [16.6, 37.2] |
| Eve+Exe | 5 (12.8\%) | [4.3, 27.4] | 5 (13.2\%) | [4.4, 28.1] | 10 (13.0\%) | [6.4, 22.6] |
| I cannot decide | 2 (5.1\%) | [0.6, 17.3] | 4 (10.5\%) | [2.9, 24.8] | 6 (7.8\%) | [2.9, 16.2] |
| PP | Arm A (\(N = 13\)) | Arm B (\(N = 18\)) | Total (\(N = 31\)) |
| n (%) | 95%-CI | n (%) | 95%-CI | n (%) | 95%-CI |
| Cap+Bev | 8 (61.5\%) | [31.6, 86.1] | 10 (55.6\%) | [30.8, 78.5] | 18 (58.1\%) | [39.1, 75.5] |
| Eve+Exe | 5 (38.5\%) | [13.9, 68.4] | 5 (27.8\%) | [9.7, 53.5] | 10 (32.3\%) | [16.7, 51.4] |
| I cannot decide | 0 | 3 (16.7\%) | [3.6, 41.4] | 3 (9.7\%) | [2.0, 25.8] |

*Physician’s preference was evaluated after 12 weeks of second-line treatment, assessed by the Physician Preference Questionnaire. Confidence interval was calculated using the Clopper-Pearson formula. Discrepancies between the sum of patients in the ITT population and the total n reported are due to patients, who did not cross over to the second-line therapy. mITT = modified ITT; ITT = intent-to-treat; PP = per-protocol; CI = confidence interval
Patient’s preference was further evaluated by age (< 60 years vs. ≥60 years) in the mITT, ITT and PP populations. Overall, a similar pattern towards a preference for Cap+Bev over Eve+Exe was observed in both age groups in all three analytical populations (data not shown).

Physician’s preference
Overall, physicians rated in 46.2% and 30.8% of their cases Cap+Bev and Eve+Exe as their preferred regimen (mITT, Table 4), respectively. A similar pattern was observed in the PP and ITT populations (Table 4).

Treatment satisfaction
The majority of the patients in the ITT population in both arms were satisfied with first-line therapy (Arm A: 76.9%; Arm B: 63.2%) and second-line therapy (Arm A: 58.8%; Arm B: 57.9%). There was no major difference between arms either in first-line therapy or in second-line therapy (Table 5).

Global health status (EORTC-QLQ-C30)
Median global health score was 50.0 during the first TP across both arms both at baseline and at week 12. There was no significant difference in the mean scores of global health status between arms in either TP (ITT, Fig. 3).

Progression-free survival
Median first-line PFS was longer (p = 0.0008) in Arm A (11.1 months) than in Arm B (3.5 months, Fig. 4a).

Table 5 Overall treatment satisfactiona (ITT population)

|                | First-line therapy | Second-line therapy |
|----------------|--------------------|---------------------|
|                | Arm A (N = 39)     | Arm B (N = 38)      | Arm A (N = 17)     | Arm B (N = 19)      |
| Satisfied      | 30 (76.9%)         | 24 (63.2%)          | 10 (58.8%)         | 11 (57.9%)          |
| Not satisfied  | 5 (12.8%)          | 7 (18.4%)           | 3 (17.6%)          | 5 (26.3%)           |
| Missing        | 2 (5.3%)           |                     | 1 (5.9%)           | 2 (10.5%)           |
| p-value        | 0.3832             |                     | 0.6243             |

*aTreatment satisfaction was evaluated in week 12 of each treatment phase, assessed by the Treatment Satisfaction Questionnaire. Second-line: Due to small n, the p-value of the asymptotic chi-square test may not be valid. The p-value of the corresponding exact test was 0.6968. Missing: Item was not answered or not evaluable. Discrepancies between the sum of answers reported and the total n are due to patients, who did not answer the whole questionnaire.

Fig. 3 EORTC-QLQ-C30 – Global Health Status. Depicted are box-and-whisker plots showing the scores of global health status in the ITT population across Arm A (Cap+Bev/Eve+Exe) and Arm B (Eve+Exe/Cap+Bev) at baseline and at week 12 in each treatment phase. The scale ranges from 0 to a maximum of 100. The horizontal solid line within each box shows the median. The line graphs display the mean Quality of Life over time per study arm. The lines extending vertically from the boxes (whiskers) indicate the variability outside the upper and lower quartiles. The whiskers span 1.5 x IQR (interquartile range, i.e. the difference between the quartiles). The individual small circles represent the outliers. EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (30-item core module); n = number; QL2 = Quality of life.
51.3% of the patients in Arm A were censored for first-line PFS. The estimated 3-month first-line PFS rate was 79.3% (95% CI: 61.4–89.6) in Arm A and 51.4% (95% CI: 34.4–65.9) in Arm B. There was no major difference ($p = 0.8345$) in median second-line PFS between Arm A (3.7 months) and Arm B (3.6 months, Fig. 4b). The estimated 3-month second-line PFS rate was similar between Arm A (62.5%; 95% CI: 34.9–81.1) and Arm B (63.2%; 95% CI: 37.9–80.4).
Overall survival
Thirty-one patients (Arm A: n = 13; Arm B: n = 18) died during the course of the study. There was no major difference \( p = 0.2088 \) in median OS between Arm A (28.8 months) and Arm B (24.7 months, Fig. 5).

Safety
Median duration of Cap+Bev therapy (first-line, 6.4 months; second-line, 4.0 months) was longer in both TPs as compared to Eve+Exe therapy (first-line, 3.4 months; second-line, 2.7 months).

Four fatal serious TEAEs (Arm A; n = 1; Arm B: n = 3) due to PD were reported during the course of the study; none were attributable to any study drug. 73.0% and 52.6% of the patients in Cap+Bev first-line and second-line therapy experienced TEAEs of CTCAE grade 3/4, respectively. 54.1% and 52.9% of the patients in Eve+Exe first-line and second-line therapy experienced TEAEs of CTCAE grade 3/4, respectively. Most common TEAEs of CTCAE grade 3/4 were observed in Arm A including hand-foot syndrome (18.9%) and hypertension (13.5%) during Cap+Bev first-line therapy, and pain (11.8%) and pneumonia (11.8%) during Eve+Exe second-line therapy (Table 6).

Discussion
Current guidelines unequivocally indicate endocrine therapy as the preferred systemic treatment in the vast majority of patients with advanced HR-positive, HER2-negative BC [2–4]. However, this is in contrast to treatment reality; 43% of these patients are primarily subjected to first-line chemotherapy with >80% receiving first-line chemotherapy when aged ≤50 years [19]. The reason for this non-adherence remains unclear at present.

Knowing patients’ treatment preference is paramount in patient care. There is a renewed interest in implementation of a shared decision-making process between patients and healthcare, ultimately enhancing treatment quality [20, 21]. Notably, it has been proven that patients with BC (16%) value the efficacy less than the side-effects [22] and are willing to make trade-offs between side-effects and different regimens [23].

Although prematurely terminated, to our knowledge the IMPROVE study is the first randomized study having evaluated patients’ preference for either combined chemo- and anti-angiogenic therapy (Cap+Bev) or combined endocrine therapy (Eve+Exe) in postmenopausal patients with advanced HR-positive, HER2-negative BC. Furthermore, IMPROVE is the first study to date having compared the efficacy outcome of endocrine-based therapy with an anti-angiogenic-based chemotherapy approach.

In this study, patients tended to favor Cap+Bev over Eve+Exe (mITT), which was in line with physicians’ preference. The potential influence from the treating physician should be taken into account. However, the primary endpoint could not be adequately assessed due to low number of observations owing to...
premature termination of the study and low number of PPQs as a high number of patients did not cross over to second-line therapy. Therefore, the data are of limited interpretability and further conclusions cannot be made. Nevertheless, despite the low number of patients in the mITT population, the data provide important and valuable novel information on patient preference regarding endocrine-based therapy versus anti-angiogenic-based chemotherapy in advanced BC. A similar tendency towards Cap+Bev as patients’ and physicians’ preferred regimen was observed in the PP population. It is intriguing to also look at the ITT population; overall, patients tended to prefer Cap+Bev over Eve+Exe. The main reason for deciding for Cap+Bev was improved QoL. However, patient-reported QoL was similar in both arms bearing in mind the large variation in QoL scores across arms and TPs. Keeping in mind the small number of evaluable questionnaires in the ITT population, it was nevertheless surprising to see Cap+Bev as the preferred regimen, despite the higher percentage of first-line grade 3/4 TEAEs observed in Arm A, possibly attributable to the differences in treatment duration between regimens.

Median first-line PFS was longer in Arm A than in Arm B. The PFS of only 3.5 months in Arm B was unexpected when comparing with the BOLERO-2 trial [10], which reported a superior median PFS of 6.9 months/10.6 months (local/central assessment) in the Eve+Exe arm. Possible reasons for the short PFS in our study include the low number of patients in each arm, the slightly shorter DFI and more prior treatments in Arm B versus Arm A, the higher percentage of comorbidities observed in Arm B (92.1%) compared to Arm A (84.6%) and a higher percentage of patients in Arm B (68.4%) with prior adjuvant treatment with anthracycline/taxane versus Arm A (56.4%), possibly reflecting a higher risk profile at initial diagnosis in Arm B. In the BOLERO-6 trial, a median PFS of 8.4 months was reported for Eve+Exe combination therapy versus median 9.6 months

Table 6 Treatment-emergent adverse events (>10% any grade; SAF population)

| Adverse event, n (%) | Arm A | Arm B |
|----------------------|-------|-------|
|                      | First-line | Second-line | First-line | Second-line |
|                      | (Cap+Bev) | (Eve+Exe) | (Cap+Bev) | (Eve+Exe) |
|                      | N=37     | N=17    | N=37     | N=19    |
| Any grade            |         |         | Any grade |         |         |
| Grade 3/4            |         |         | Grade 3/4 |         |         |
| Anemia               | 1 (2.7%)| 4 (23.5%)| 5 (13.5%)|         |         |
| Arthralgia           | 5 (13.5%)| 4 (10.8%)| 1 (5.3%)|         |         |
| Bone pain            | 3 (8.1%)| 6 (16.2%)|         |         |         |
| Cough                | 5 (13.5%)| 3 (17.6%)| 6 (16.2%)| 2 (10.5%)|         |
| Decreased appetite   | 6 (16.2%)| 1 (5.9%)| 5 (13.5%)|         |         |
| Diarrhea             | 12 (32.4%)| 2 (11.8%)| 11 (29.7%)| 5 (26.3%)|         |
| Dyspnea              | 6 (16.2%)| 3 (17.6%)| 4 (10.8%)| 4 (21.1%)|         |
| Fatigue              | 13 (35.1%)| 3 (17.6%)| 6 (16.2%)| 2 (10.5%)|         |
| Hand-Foot Syndrome   | 21 (56.8%)| 7 (18.9%)| 1 (2.7%)| 6 (31.6%)| 2 (10.5%)|
| Headache             | 6 (16.2%)|         | 6 (16.2%)|         |         |
| Hypertension         | 11 (29.7%)| 5 (13.5%)| 2 (5.4%)| 3 (15.8%)|         |
| Mucosal inflammation | 4 (10.8%)| 2 (11.8%)| 7 (18.9%)|         |         |
| Nausea               | 15 (40.5%)| 1 (5.9%)| 9 (24.3%)| 5 (26.3%)|         |
| Edema peripheral     | 2 (5.4%)|         | 6 (16.2%)| 2 (10.5%)|         |
| Pain                 | 2 (5.4%)| 2 (11.8%)| 2 (11.8%)| 1 (2.7%)|         |
| Pleural effusion     | 2 (5.4%)|         | 2 (5.4%)| 3 (15.8%)|         |
| Pneumonia            | 2 (11.8%)|         | 3 (8.1%)|         |         |
| PSN                  | 6 (16.2%)| 1 (2.7%)| 2 (10.5%)|         |         |
| Stomatitis           | 9 (24.3%)| 1 (5.9%)| 5 (13.5%)| 1 (5.3%)|         |

Percentages in second-line therapy refer to the number of patients, who started second-line therapy. Time range: from first administration of study treatment until 30 days after end of treatment in each treatment line. Unrelated TEAEs starting within 30 days of end of first-line therapy and after start of second-line therapy were considered treatment-emergent in both treatment lines in case second-line therapy had started within 30 days of end of first-line therapy. MedDRA v20.0. PSN = Peripheral sensory neuropathy
for Cap monotherapy [24]; although not directly comparable, these results point towards the data in our study. Due to a high number of censored cases in the present study, the OS data are not further interpretable. The safety profile in this study was consistent with current SmPC of respective drug [8, 9, 12, 13].

**Conclusion**

Although prematurely terminated, to our knowledge the IMPROVE study is the first randomized study having evaluated patients’ preference for either combined chemo- and anti-angiogenic therapy (Cap+Bev) or combined endocrine therapy (Eve+Exe) in postmenopausal patients with advanced HR-positive, HER2-negative BC. There was a tendency to favor Cap+Bev over Eve+Exe, which was in line with physicians’ preference. The efficacy of Cap+Bev proved to be superior in terms of first-line PFS. Patient-reported QoL was similar in both arms. No new safety signals were reported.

**Abbreviations**

BC: Breast cancer; Bev: Bevacizumab; Cap: Capecitabine; CTCAE: Common Terminology Criteria for Adverse Events; DFI: Disease-free interval; ECOG: Eastern Cooperative Oncology Group; EORTC: European Organisation for Research and Treatment of Cancer; Eve: Everolimus; Exe: Exemestane; FU: Follow up; HER2: Human epidermal growth factor receptor 2; HR: Hormone receptor; ITT: Intent-to-treat; MBC: Metastatic BC; mITT: Modified ITT; mTOR: Mammalian target of rapamycin; NCT: National Cancer Institute; OS: Overall survival; PD: Progressive disease; PFS: Progression-free survival; PP: Per-protocol; PPQ: Patient preference questionnaire; QoL: Quality of life questionnaire; QoL: Quality of life; RECIST: Response Evaluation Criteria In Solid Tumors; SAF: Safety set; SmPC: Summary of Product Characteristics; TEAE: Treatment-emergent adverse event; TP: Treatment phase.

**Acknowledgements**

The authors thank all patients, physicians and study teams participating in this study. We would also like to thank Dr. med. Norbert Marschner (iOMEDICO), Dr. med. Jens Hasskarl (iOMEDICO), Dr. med. Kirsten Hauswald (iOMEDICO), and Dr. med. Tanja Trarbach (iOMEDICO) for support during study design, Melanie Frank (iOMEDICO) for writing the statistical analysis plan and for performing a large part of the statistical analysis, Dr. med. Leonora Hout (iOMEDICO) for support during data analysis and critical review of the manuscript, Dr. Andrea Kriemen (iOMEDICO) for support during the writing of the study protocol, and Dr. Christian Johansson (iOMEDICO) for the writing of the clinical study report and preparation of the manuscript. This project was supported financially by Novartis Pharma GmbH, Germany.

**Consent to publish**

Not applicable.

**Authors’ contributions**

TD, JF, MI, ER and KP were involved in conception and design, analysis and interpretation of the data, and reviewed the paper for intellectual content and gave their approval of the final version of the manuscript to be published. MC performed statistical analysis, analyzed and interpreted the data, and reviewed the paper for intellectual content and approved the final version of the manuscript to be published. US, AH, CM, CMK, UVK, DS, PK and VH collected data and reviewed the paper for intellectual content and gave their approval of the final version of the manuscript to be published.

**Funding**

This iOMEDICO-sponsored project received financial support from Novartis Pharma GmbH, Germany. Novartis had no role in the study design, data collection and analysis, interpretation of results, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

Clinical data were documented in electronic Case Report Forms (eCRFs; iostudy office edc; iOMEDICO) and are the property of iOMEDICO. The data are not publicly available due to them containing information that could compromise patient and/or research participant privacy / consent.

**Ethics approval and consent to participate**

The study protocol was approved by all relevant bodies (BfArM, Bonn, Germany). The study received positive opinions from the consulting Ethics Committee of the State Chamber of Physicians at the Federal States of Berlin, Bremen, Dessau-Roßlau, Dresden, Düsseldorf, Frankfurt a.M., Hamburg, Hannover, Mainz, München, Münster, Saarbrücken and Stuttgart as well as from the Ethics Committees at the Medical Faculty of the Universities of Bochum, Essen, Greifswald, Heidelberg, Mannheim and Würzburg, Germany. The study was conducted in accordance with Good Clinical Practice and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study adheres to CONSORT guidelines. Written informed consent was obtained from all individual participants included in the study.

**Competing interests**

Thomas Decker: CONSULTANT OR ADVISORY ROLE: Novartis. Ulrike Sölting: No conflict of interest. Antje Hahn: No conflict of interest. Christoph Maintz: No conflict of interest. Christian Martin Kurbacher: HONORARIA: Amgen, Eli Lilly, Mundipharma, Novartis, Pfizer, Roche, Tesaro; CONSULTANT OR ADVISORY ROLE: Amgen, Eli Lilly, Mundipharma, Novartis, Pfizer, Riemsler, Roche, Tesaro, RESEARCH FUNDING: Astra Zeneica, MSD Sharp & Dohme (Merck), Novartis, Pfizer, Seattle Genetics; TRAVEL, ACCOMMODATIONS: Amgen, Hexal, PharmaMar, Pfizer, Tesaro. Ursula Vehling-Kaiser: No conflict of interest. Dagmar Sent: No conflict of interest. Peter Klar: No conflict of interest. Volker Hagen: HONORARIA: Amgen, BMS, Celgene, Forn, Gilead, Janssen Cilag, IOMEDICO, Pfizer, Roche; SHAREHOLDINGS: Bristol-Myers Squibb, Johnson & Johnson. Marco Chiabudini: No conflict of interest. Julia Falkenstein: No conflict of interest. Martin Indorf: No conflict of interest. Eva Runkel: No conflict of interest. Karin Pothoff: No conflict of interest.

**Author details**

1Gemeinschaftspraxis für Hämatologie und Onkologie GbR, Elisabethenstrasse 19, 88212 Ravensburg, Germany. 2Onkologische Gemeinschaftspraxis, Goethestrasse 47, 34119 Kassel, Germany. 3Klinikum Mittelbaden Baden-Baden Bühl, Balger Strasse 50, 76532 Baden-Baden Weststadt, Germany. 4Hämatologisch-Onkologische Praxis, Mauerfeldchen 72, 52146 Würselen, Germany. 5Gynäkologisches Zentrum Bonn, Friedenplatz 16, 53111 Bonn, Germany. 6Hämatologisch-onkologische Tagesklinik, Achdorfer Weg 5, 84036 Landshut, Germany. 7Klinikum Leverkusen gGmbH, Am Gesundheitspark 11, 51375 Leverkusen, Germany. 8MediOnko-Institut GbR, Mollendorffstr. 52, 10367 Berlin, Germany. 9St-Johannes-Hospital, Johannesstr. 9-17, 44137 Dortmund, Germany. 10iOMEDICO AG, Ellen-Gottlieb-Straße 19, 79106 Freiburg im Breisgau, Germany.

Received: 18 October 2019 Accepted: 12 March 2020

Published online: 06 April 2020

**References**

1. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20-9. https://doi.org/10.1634/theoncologist.10-90003-20.
2. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Steams V, Winer EP, Griggs JJ.
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol Off J Am Soc Clin Oncol. 2018;JCO1801160 https://doi.org/10.1200/JCO.18.01160.

3. Cardoso F, Senkus E, Costa A, Papadopoulou E, Ascop M, André F, Harbeck N, Lopez BA, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghri NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Kroop IE, Mayer M, Nakigudde G, Ofrissen BV, Ohno S, Pagani O, Paluch-Shimon S, Pentaloudi F, Prat A, Rugo HS, Sledge GW, Spence D, Thomasen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol Off J Eur Soc Med Oncol. 2019;20:1364–57 https://doi.org/10.1016/annonc/mdy192.

4. O’Sullivan CC, Loprinzi CL, Haddad TC. Updates in the evaluation and management of breast cancer. Mayo Clin Proc. 2018;93:794–807 https://doi.org/10.1016/j.mayocp.2018.03.025.

5. Wilkens N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2000;CD001747 https://doi.org/10.1002/14651858.CD001747.

6. Miller KD, Chap LL, Holmes FA. Randomized phase III trial of Capecitabine compared with Bevacizumab plus Capecitabine in patients with previously treated metastatic breast Cancer. J Clin Oncol. 2005;23:792–9 https://doi.org/10.1200/JCO.2005.05.098.

7. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SYT, Zhou X, Phan S-C, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1252–60 https://doi.org/10.1200/JCO.2010.28.0982.

8. Avastin 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (eMC). n.d. https://www.medicines.org.uk/emc/product/1319/smpc. Accessed 6 Apr 2018.

9. Xeloda 150mg and 500mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC). n.d. https://www.medicines.org.uk/emc/product/1319/smpc. Accessed 6 Apr 2018.

10. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Grant M, Pritchard KI, Lebrun F. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012; 366:50–9.

11. Yardley DA, Noguchi S, Pritchard KI, Lebrun F, Everolimus plus Exemestane in postmenopausal women with hormone receptor positive HER2-negative advanced breast cancer: the BOLERO-2 randomized, double-blind, placebo-controlled, phase III trial of capecitabine monotherapy for estrogen receptor-positive, HER2-negative metastatic breast cancer. J Clin Oncol Off J Eur Soc Med Oncol. 2013;31:2432–49 https://doi.org/10.1817/CEJON.2013-004537.

12. Afinitor 10mg tablets - Summary of Product Characteristics (SmPC) - (eMC). n.d. https://www.medicines.org.uk/emc/product/6658/smpc. Accessed 6 Apr 2018.

13. Aromasin - Summary of Product Characteristics (SmPC) - (eMC). n.d. https://www.medicines.org.uk/emc/product/5520. Accessed 6 Apr 2018.

14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Venne J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47 https://doi.org/10.1016/j.ejca.2008.10.026.

15. Aaronsen NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filliberti A, Flechtmann H, Fleshman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85: 365–76.

16. CTCAE v4.0 - 2010-06-14 QuickReference_Sx7.pdf. n.d. https://www.eortc.be/services/doc/ct/CTCAE_v4.0-2010-06-14_QuickReference_Sx7.pdf. Accessed 6 Apr 2018.

17. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, Giorgi UD, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmut F, Cellà D. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;JCO. 2013.50.8267 https://doi.org/10.1200/JCO.2013.50.8267.

18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81 https://doi.org/10.2307/2281868.

19. Hartkopf AD, Hueber J, Volz B, Nabieva N, Taran F-A, Schwilutja J, Overkamp F, Kolberg H-C, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Luftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hiesicher C, Geberth M, Fessis N, Abenhartid W, Kurbacher C, Wuerstlein R, Thomsen C, Untch M, Fasching PA, Jann W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2-negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast. 2017;37:42–51 https://doi.org/10.1016/j.breast.2017.10.002.

20. Berger AM, Buzalko RK, Kupoyka YA, Gardner BJ, Djajilova DM, Otte JL. Preferences and actual chemotherapy decision-making in the greater plains collaborative breast cancer study. Acta Oncol Stockh Swed. 2017;56:1690–7 https://doi.org/10.1080/0284186X.2017.1374555.

21. Gustafson A. Reducing patient uncertainty: implementation of a shared decision-making process enhances treatment quality and provider communication. Clin J Oncol Nurs. 2017;21:113–5 https://doi.org/10.1188/17.CJON.113-115.

22. Wouters H, Maatman GA, Van Dijk L, Bouvy ML, Vree R, Van Geffen ECG, Norrier JW, Stiggelbout AM. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:2324–9 https://doi.org/10.1093/annonc/mdt195.

23. Beustien K, Grinspan J, Kuchuk I, Mazzareleo S, Dent S, Gertler S, Bouganim N, Vandemeer L, Clemmons M. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist. 2014; 19:127–34 https://doi.org/10.1634/theoncologist.2013-0359.

24. Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, Özgüroğlu M, Lundherr H, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau A-L, Burris H. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol. 2018;4:182262 https://doi.org/10.1001/jamaoncol.2018.2262.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.